MXCT
MaxCyte Inc.
Company Overview
| Mkt Cap | $162.04M | Price | $1.04 |
| Volume | 1.02M | Change | -4.59% |
| P/E Ratio | -3.6 | Open | $1.09 |
| Revenue | $33.0M | Prev Close | $1.09 |
| Net Income | $-44.6M | 52W Range | $0.64 - $2.47 |
| Div Yield | N/A | Target | $4.67 |
| Overall | 49 | Value | 60 |
| Quality | 31 | Technical | 58 |
No chart data available
About MaxCyte Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Latest News
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ramsay Health Care (OtherRMSYF) and MaxCyte (MXCT)
Craig-Hallum Remains a Buy on MaxCyte (MXCT)
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MXCT | $1.04 | -4.6% | 1.02M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |